.Attribute Medication, Published online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the observational SCRUM-Japan GOZILA research, after a typical consequence of 11 months, patients along with metastatic stomach tumors that received biomarker-matched therapies based on flowing lump DNA profiling presented a greater professional perk than those obtaining unparalleled therapy.